Ophthotech Corp. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
Sales/Revenue
-
41,259.00
51,505.00
50,909.00
209,977.00
Cost of Goods Sold (COGS) incl. D&A
20.00
-
-
-
-
Gross Income
20.00
-
-
-
-
SG&A Expense
47,405.00
121,645.00
174,335.00
245,716.00
86,109.00
EBIT
47,425.00
80,513.00
123,528.00
195,564.00
121,105.00
Unusual Expense
2,266.00
-
-
-
13,100.00
Non Operating Income/Expense
-
-
53.00
34.00
34.00
Interest Expense
1,454.00
-
-
-
-
Pretax Income
51,145.00
80,296.00
122,504.00
193,826.00
109,493.00
Income Tax
-
17,892.00
16,787.00
406.00
4,712.00
Consolidated Net Income
51,145.00
98,188.00
105,717.00
193,420.00
114,205.00
Net Income
51,145.00
98,188.00
105,717.00
193,420.00
114,205.00
Net Income After Extraordinaries
51,145.00
98,188.00
105,717.00
193,420.00
114,205.00
Net Income Available to Common
57,036.00
98,188.00
105,717.00
193,420.00
114,205.00
EPS (Basic)
6.34
2.95
3.06
5.45
3.17
Basic Shares Outstanding
9,003.00
33,258.00
34,580.00
35,486.00
35,919.00
EPS (Diluted)
6.34
2.95
3.06
5.45
3.17
Diluted Shares Outstanding
9,003.00
33,258.00
34,580.00
35,486.00
36,007.00
EBITDA
47,405.00
80,386.00
122,830.00
194,807.00
123,868.00
Non-Operating Interest Income
-
217.00
971.00
1,704.00
1,522.00
Preferred Dividends
5,891.00
-
-
-
-

About Ophthotech

View Profile
Address
One Penn Plaza
New York New York 10119
United States
Employees -
Website http://www.ophthotech.com
Updated 09/14/2018
Ophthotech Corp. is a biopharmaceutical company,which engages in discovering, developing, and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R.